TechnoPhage, a Portuguese company specializing in GMP phage development, and PHAXIAM Therapeutics, a biopharmaceutical firm focused on innovative treatments for severe and resistant bacterial infections, announced a strategic collaboration. This partnership aims to provide physicians with access to a comprehensive GMP phage portfolio, facilitating the implementation of Individualized Phage Therapies (IPT) through shared capabilities.
By combining PHAXIAM’s GMP phage portfolio and advanced diagnostic capabilities, including its phagogram-based approach, with TechnoPhage’s GMP phage portfolio and manufacturing expertise, the collaboration seeks to deliver a faster and more effective response to the growing challenge of severe resistant infections.
The partnership plans to expand the number and diversity of GMP phages available for IPT, targeting at least seven critical pathogens: Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii, among others. These pathogens account for approximately 70% of the most prevalent severe resistant infections.
The collaboration aims to achieve a collection of 25 GMP phages by the end of 2025 and 35-40 GMP phages by the end of 2026, significantly enhancing the resources available for combating resistant bacterial infections.
This strategic partnership represents a significant advancement in the field of bacteriophage therapy, offering hope for more effective treatments against some of the most challenging bacterial pathogens.
